BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Lobbying for BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Expenses

$220,000.00

What this organization spent lobbying with its own staff. Reported using B: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 8

HR 8646
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
HR 9620
Military Next-Gen Collision Avoidance Act of 2026
S 4189
INSULIN Act of 2026
S 4612
SCREEN for Type 1 Diabetes Act of 2026
HR 9000
SCREEN for Type 1 Diabetes Act of 2026
HR 5467
PAAT Act
119-S-8270
Not yet in our database
HR 8018
ISLET Act

Lobbying activity 2

Budget/Appropriations

H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027; H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; Issues pertaining to NIH & FDA funding.

Health Issues

S. 4189 - the INSULIN Act; S. 4612/H.R. 9000 - the SCREEN For T1D Act; S. 4612, the SCREEN for T1D Act; H.R. 5467 - the Patient Access to Autoimmune Treatments Act; S. 8270/H.R. 8018 - the ISLET Act; Issues pertaining to cell and gene therapies; Issues pertaining to C-peptide; Issues pertaining to NIH research; Issues pertaining to Special Diabetes Program.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.